News

Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered once a month that has been approved by the FDA since 2006 for wet AMD.
Analysts at GlobalData think that faricimab and another Roche-developed product will be the main derivers of the market in the coming years. The companion product – Susvimo – is an implantable ...
8 Beyond the injectable treatments, the port delivery system (Susvimo, Roche) with ranibizumab, gene therapy, nanoparticles for drug delivery, and other targeted therapies are newest and future ...
Here's why La Roche-Posay is pulling its Effaclar Duo Acne Spot Treatment from retail shelves. La Roche-Posay is a brand under the L'Oreal Group umbrella. A La Roche-Posay spokesperson confirmed ...
Roche has secured its third antibody-drug conjugate pact of the year, this time agreeing to hand $36 million in upfront payments to Oxford BioTherapeutics. The agreement will also see U.K.-based ...
Roche is meanwhile tying up with Denmark's Zealand Pharma to invent a better GLP-1 weigh-loss drug. Despite these developments, Novo Nordisk stock remains the most attractively valued GLP-1 ...
Two months after U.S. President Donald Trump issued an executive order proclaiming diversity, equity and inclusion (DEI) programs “illegal and immoral,” Roche has scrapped its high-profile ...
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipeline. The outlay, plus up to $3.6 billion in milestones, has secured Roche the right to codevelop and ...
The moment every 1923 fan has been waiting for has finally arrived. In this week’s episode, Father Renaud (Sebastian Roché) finally catches up with Teonna Rainwater (Aminah Nieves). After ...